Streetbeat News

Regulatory

TSLA

Wedbush analyst Dan Ives predicts China will retaliate against the U.S. if tariffs on electric vehicle imports from China are increased. The Biden administration plans to raise tariffs on China's EVs from 25% to around 100%, with an additional 2.5% duty on all imported cars. This move could challenge Tesla Inc. and other U.S. automakers in the EV market and escalate trade tensions.

Portfolio Pulse from Anan Ashraf

May 11, 2024 | 9:20 am

CURLF

TCNNF

Beacon Securities and Needham reports highlight Q1 2024 financials for Curaleaf and Trulieve, respectively, with Curaleaf posting $339M in revenue and Trulieve $297.6M. Both companies are navigating regulatory changes positively, with Curaleaf focusing on strategic financial management and Trulieve on operational strengths and market opportunities. Legislative changes are expected to further benefit both companies.

Portfolio Pulse from Nicolás Jose Rodriguez

May 10, 2024 | 10:42 pm

EVAX

Evaxion Biotech A/S received a notification from Nasdaq for not meeting the minimum stockholders' equity requirement.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 9:03 pm

ZEPP

Zepp Health Corporation received a NYSE non-compliance letter due to the low trading price of its ADSs, indicating it's below the required compliance standards.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 9:02 pm

UONE

UONEK

Urban One has announced through an SEC filing that it does not expect any changes to its previously audited financial statements. This statement suggests stability in the company's financial reporting and compliance with regulatory standards.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:51 pm

UONE

UONEK

Urban One has disclosed material weaknesses in its internal control over financial reporting, expecting some controls to be ineffective as of December 31, 2023, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:51 pm

NEGG

Newegg Commerce, Inc. received a Nasdaq notification for not meeting the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive days. The company's listing remains unaffected for now.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:35 pm

HSCS

Heart Test Laboratories received a staff determination from Nasdaq on May 9 to delist the company's securities from the Nasdaq Capital Market, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:33 pm

CTCX

Carmell Therapeutics has filed with the SEC for the resale of up to 1.3 million common shares by the selling stockholders. This move indicates a potential increase in the company's public float, which could have various impacts on its stock price.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:31 pm

ME

23andMe Holding has been granted an additional 180 days, until November 4, to regain compliance with the minimum bid price requirement for continued listing, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:30 pm